Recent Research

2021

Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, Goere D, Baratti D, Nizri E, Morris DL, Glehen O, Sardi A, Barrios P, Quénet F, Villeneuve L, Gómez-Portilla A, de Hingh I, Ceelen W, Pelz JOW, Piso P, González-Moreno S, Van Der Speeten K, Deraco M; Peritoneal Surface Oncology Group International (PSOGI) and the French National Registry of Rare Peritoneal Surface Malignancies (RENAPE). The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surg. 2021 Jan 27:e206363. doi: 10.1001/jamasurg.2020.6363. Online ahead of print. PMID: 33502455

Rufián-Andujar B, Valenzuela-Molina F, Rufián-Peña S, Casado-Adam Á, Sánchez-Hidalgo JM, Rodríguez-Ortiz L, Medina-Fernández FJ, Díaz-López C, Ortega-Salas R, Martínez-López A, Briceño-Delgado J, Romero-Ruíz A, Arjona-Sánchez Á. From the Ronnett to the PSOGI Classification System for Pseudomyxoma Peritonei: A Validation Study. Ann Surg Oncol. 2021 Jan 20. doi: 10.1245/s10434-020-09560-w. Online ahead of print. PMID: 3347126.

Soucisse ML, Fisher O, Liauw W, Ghanipour L, Cashin P. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with or without early post-operative intraperitoneal chemotherapy for appendix neoplasms with peritoneal metastases: A propensity score analysis. Eur J Surg Oncol. 2021 Jan;47(1):157-163. doi: 10.1016/j.ejso.2020.08.026. Epub 2020 Sep 6. PMID: 32943277.

Arjona-Sanchez Á, Valenzuela-Molina F, Rufian-Andujar B, Romero-Ruiz A. ASO Author Reflection: The End of the Tower of Babel in Pseudomyxoma Peritonei. Ann Surg Oncol. 2021 Jan 22. doi: 10.1245/s10434-021-09600-z. Online ahead of print. PMID: 33481126.

Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S; List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. Eur J Surg Oncol. 2021 Jan;47(1):4-10. doi: 10.1016/j.ejso.2019.03.012. Epub 2019 Mar 23. PMID: 30954350 Review.

2020

Arjona-Sanchez A, Aziz O, Passot G, Salti G, Esquivel J, Van der Speeten K, Piso P, Nedeclut S, Sommariva A, Yonemura Y, Turaga K, Selvasekar CR, Rodriguez-Ortiz L, Sanchez-Hidalgo JM, Casado-Adam A, Rufian-Peña S, Briceño J, Glehen O. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. Eur J Surg Oncol. 2020 Dec 2:S0748-7983(20)31036-2. doi: 10.1016/j.ejso.2020.11.140. Online ahead of print. PMID: 33298341.

Mercier F, Jeremie G, Alyami M, Delphine V, Vahan K, Pascal R, Sylvie I, Guillaume P, Olivier G. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. Surg Endosc. 2020 Nov;34(11):4916-4923. doi: 10.1007/s00464-019-07280-1. Epub 2019 Dec 2. PMID: 31792692.

Calabrò ML, Lazzari N, Rigotto G, Tonello M, Sommariva A. Role of Epithelial-Mesenchymal Plasticity in Pseudomyxoma Peritonei: Implications for Locoregional Treatments. Int J Mol Sci. 2020 Nov 30;21(23):9120. doi: 10.3390/ijms21239120. PMID: 33266161.

Swain D, Mason G, Yates A, Burke S, Cecil T, Mohamed F, Dayal S, Tzivanakis A, Moran B. Outcomes of home parenteral nutrition in 34 patients with intestinal failure from recurrent or progressive peritoneal malignancy of gastro-intestinal tract origin. Eur J Clin Nutr. 2020 Nov 21. doi: 10.1038/s41430-020-00810-4. Online ahead of print. PMID: 33221816.

Sgarbura O, Al Hosni M, Petruzziello A, Figueroa R, Khellaf L, Pissas MH, Carrère S, Nougaret S, Bibeau F, Quénet F. Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept. Int J Hyperthermia. 2020;37(1):585-591. doi: 10.1080/02656736.2020.1772511. PMID: 32484014.

Shariff US, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Mode of Presentation in 1070 Patients With Perforated Epithelial Appendiceal Tumors, Predominantly with Pseudomyxoma Peritonei. Dis Colon Rectum. 2020 Sep;63(9):1257-1264. doi: 10.1097/DCR.0000000000001682. PMID: 33216496.

Prabhu A, Brandl A, Wakama S, Sako S, Ishibashi H, Mizumoto A, Takao N, Noguchi K, Motoi S, Ichinose M, Liu Y, Yonemura Y. Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei-A Novel Treatment Approach. Cancers (Basel). 2020 Aug 7;12(8):2212. doi: 10.3390/cancers12082212. PMID: 32784670.

Arjona-Sánchez A, Cortés-Guiral D, Duran-Martínez M, Villarejo-Campos P, Sánchez-Hidalgo JM, Casado-Adam A, Rodriguez-Ortiz L, Romero-Ruiz A, Rufian-Andujar B, Espinosa-Redondo E, Valenzuela-Molina F, Rufián-Peña S and Briceño-Delgado J. Complete laparoscopic pelvic peritonectomy plus hyperthermic intraperitoneal chemotherapy. Tech Coloproctol. 2020 Jul 28. doi: 10.1007/s10151-020-02277-8. Online ahead of print. DOI: 10.1007/s10151-020-02277-8. PMID: 32725353.

Flatmark K and Mohamed F. ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. Surg Pathol Clin. 2020 Sep;13(3):469-484. doi: 10.1016/j.path.2020.05.006. Epub 2020 Jul 11. PMID: 32773195

Carr NJ. Updates in Appendix Pathology: The Precarious Cutting Edge. Surg Pathol Clin. 2020 Sep;13(3):469-484. doi: 10.1016/j.path.2020.05.006. Epub 2020 Jul 11. DOI: 10.1016/j.path.2020.05.006. PMID: 32773195

Garach NR, Kusamura S, Guaglio M, Bartolini V, Deraco M, Baratti D. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2020 Aug 25:S0748-7983(20)30709-5. doi: 10.1016/j.ejso.2020.08.017. Online ahead of print. PMID: 33280949.

Nummela P, Heiskanen A, Kytölä S, Haglund C, Lepistö A, Satomaa T, Ristimäki A. Altered linkage pattern of N-glycan sialic acids in pseudomyxoma peritonei. Glycobiology. 2020 Aug 17:cwaa079. doi: 10.1093/glycob/cwaa079. Online ahead of print. PMID: 33539510.

Patrick-Brown TDJH, Carr NJ, Swanson DM, Larsen S, Mohamed F, Flatmark K. Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. Ann Surg Oncol. 2020 Jun 2. doi: 10.1245/s10434-020-08655-8. PMID: 32488520

Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, Kepenekian V, Deraco M, Glehen O, Moran BJ, PSOGI. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2020 Feb 28;S0748-7983(20)30114-1. doi: 10.1016/j.ejso.2020.02.012. PMID: 32199769

Roy A, Stanford S, Nunn S, Alves S, Sargant N, Rangarajan S, Arbuthnot Smith E, Bell J, Dayal S, Cecil T, Tzivanakis A, Kruzhkova I, Solomon C, Knaub S, Moran B, Mohamed F. Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei. J Thromb Haemost. 2020 Feb;18(2):352-363.Epub 2019 Nov 26. doi: 10.1111/jth.14665. PMID: 31654548

Sommariva A, Tonello M, De Simoni O, Barina A, Riccardo Rossi C, Pilati P. Laparoscopic hyperthermic intraperitoneal chemotherapy for appendiceal tumors. Asian J Endosc Surg. 2020 Jan 29. doi: 10.1111/ases.12784. [Epub ahead of print] PubMed PMID: 31997552.

2019

Houlzé-Laroye C, Eveno C. Low-grade appendiceal mucinous neoplasms with bowel obstruction. Pleura Peritoneum. 2019 Oct 1;4(3):20190020. doi: 10.1515/pp-2019-0020. eCollection 2019 Sep 1. PubMed PMID: 31667332; PubMed PMCID: PMC6812216.

Al-Azzawi M, Misdraji J, van Velthuysen MF, Shia J, Taggart MW, Yantiss RK, Svrcek M, Carr N. Acellular mucin in pseudomyxoma peritonei of appendiceal origin: what is adequate sampling for histopathology? J Clin Pathol. 2019 Oct 13. pii: jclinpath-2019-206213. doi: 10.1136/jclinpath-2019-206213. [Epub ahead of print] PubMed PMID: 31611287.

Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei. Clin Exp Metastasis. 2019 Dec;36 (6):511-518. doi: 10.1007/s10585-019-09991-0. Epub 2019 Sep 20. PubMed PMID: 31541325. PubMed PMCID: PMC6834750.

Solomon D, Bekhor E, Leigh N, Maniar YM, Totin L, Hofstedt M, Aycart SN, Carr J, Ballentine S, Magge DR, Golas BJ, Pai RK, Polydorides AD, Bartlett DL, Labow DM, Choudry HA, Sarpel U. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience. Ann Surg Oncol. 2019 Aug 5. doi:10.1245/s10434-019-07678-0. [Epub ahead of print] Erratum in: Ann Surg Oncol. 2019 Aug 19; PubMed PMID: 31385130.

Kusamura S, Azmi N, Fumagalli L, Baratti D, Guaglio M, Cavalleri A, Garrone G, Battaglia L, Barretta F, Deraco M. Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). Eur J Surg Oncol. 2019 Jun 21. pii:S0748-7983(19)30516-5. doi: 10.1016/j.ejso.2019.06.022. [Epub ahead of print] Review. PubMed PMID: 31262599.

Bartoş A, Bartoş D, Raluca S, Mitre C, Hadade A, Iancu I, Cioltean C, Iancu C, Militaru C, Părău A, Breazu C. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: Our Initial Experience. Chirurgia (Bucur). 2019 Mar-Apr;114(2):222-233. doi: 10.21614/chirurgia.114.2.222. PubMed PMID: 31060655.

Raimondi A, Corallo S, Niger M, Antista M, Randon G, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F. Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. Clin Colorectal Cancer. 2019 Jun;18 (2):e179-e190. doi: 10.1016/j.clcc.2019.03.002. Epub 2019 Apr 1. PubMed PMID: 31023524.

Mercier F, Dagbert F, Pocard M, Goéré D, Quenet F, Wernert R, Dumont F, Brigand C, Passot G, Glehen O; RENAPE Network. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open. 2018 Sep 27;3 (2):195-202. doi: 10.1002/bjs5.97. eCollection 2019 Apr. PubMed PMID: 30957067; PubMed PMCID: PMC6433307.

Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S; List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. Eur J Surg Oncol. 2019 Mar 23. pii: S0748-7983(19)30337-3. doi: 10.1016/j.ejso.2019.03.012. [Epub ahead of print] Review. PubMed PMID: 30954350.

Swain DR, Yates AL, Mohamed F, Dayal SP, Tzivanakis A, Cecil TD, Moran BJ. Do patients undergoing cytoreductive surgery and HIPEC for peritoneal malignancy need parenteral nutrition? Pleura Peritoneum. 2018 Oct 2;3(4):20180123. doi: 10.1515/pp-2018-0123. eCollection 2018 Dec 1. PubMed PMID: 30911667; PubMed PMCID: PMC6404997 .

Barral M, El Sanharawi I, Eveno C, Dohan A, Launay JM, Lo Dico R, Pocard M, Bonnin P. Post-operative wall shear stress in the superior mesenteric artery: Biomarker of long term outcome in patients with residual disease after incomplete cytoreductive surgery for pseudomyxoma peritonei. Eur J Surg Oncol. 2019 Sep;45(9):1727-1733. doi: 10.1016/j.ejso.2019.03.001. Epub 2019 Mar 6. PubMed PMID: 30871885.

2018

Dohan A, Bouquot M, Rousset P, Eveno C. ASO Author Reflections: Proposal of a New Preoperative Score to Predict Resectability in Pseudomyxoma Peritonei. Ann Surg Oncol. 2018 Dec 12. doi: 10.1245/s10434-018-7012-6. [Epub ahead of print] PubMed PMID: 30542837.

Kurtz F, Struller F, Horvath P, Solass W, Bösmüller H, Königsrainer A, Reymond MA. Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study. Gastroenterol Res Pract. 2018 Oct 24;2018:2743985. doi: 10.1155/2018/2743985. eCollection 2018. PubMed PMID: 30473706; PubMed PMCID: PMC6220392.

Thorgersen EB, Melum E, Folseraas T, Larsen SG, Line PD. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report. World J Surg Oncol. 2018 Sep 5;16(1):180. doi:10.1186/s12957-018-1482-7. PubMed PMID: 30185175; PubMed PMCID: PMC6126040.

Galan A, Rousset P, Mercier F, Képénékian V, Valette PJ, Glehen O, Passot G. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia. Eur J Surg Oncol. 2018 Nov;44(11):1818-1823. doi: 10.1016/j.ejso.2018.07.060. Epub 2018 Aug 11. PubMed PMID: 30143249.

Saarinen L, Nummela P, Leinonen H, Heiskanen A, Thiel A, Haglund C, Lepistö A, Satomaa T, Hautaniemi S, Ristimäki A. Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei. Mol Cell Proteomics. 2018 Nov;17(11):2107-2118. doi: 10.1074/mcp.RA118.000615. Epub 2018 Aug 2. PubMed PMID:30072579; PPMCID: PMC6210226.

Nizri E, Kusamura S, Fallabrino G, Guaglio M, Baratti D, Deraco M. Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC. AnnSurg Oncol. 2018 Oct;25(11):3264-3270. doi: 10.1245/s10434-018-6630-3. Epub 2018 Jul 26. PubMed PMID: 30051371.

Govaerts K, Chandrakumaran K, Carr NJ, Cecil TD, Dayal S, Mohamed F, Thrower A, Moran BJ. Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei. Eur J Surg Oncol. 2018 Sep;44(9):1371-1377. doi: 10.1016/j.ejso.2018.06.023. Epub 2018 Jul 6. PubMed PMID: 30017331.

Arjona-Sánchez Á, Rodríguez-Ortiz L, Rufián-Peña S, Sánchez-Hidalgo JM, Briceño-Delgado J. Laparoscopic approach in complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy by CO(2) closed system in a low grade pseudomyxoma peritonei. Cir Esp. 2018 Dec;96(10):656-658. doi: 10.1016/j.ciresp.2018.03.013. Epub 2018 Jun 22. English, Spanish. PubMed PMID: 29937297.

Pengelly RJ, Rowaiye B, Pickard K, Moran B, Dayal S, Tapper W, Mirnezami A, Cecil T, Mohamed F, Carr N, Ennis S. Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei. J Mol Diagn. 2018 Sep;20(5):635-642. doi: 10.1016/j.jmoldx.2018.05.002. Epub 2018 Jun 22. PubMed PMID: 29936255.

Arjona-Sanchez A, Rufian-Peña S, Sanchez-Hidalgo JM, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience. World J Surg. 2018 Oct;42(10):3120-3124. doi: 10.1007/s00268-018-4634-6. PubMed PMID: 29691625.

Bignell MB, Mehta AM, Alves S, Chandrakumaran K, Dayal SP, Mohamed F, Cecil TD, Moran BJ. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer. Colorectal Dis. 2018 Aug;20(8):704-710. doi: 10.1111/codi.14057. PubMed PMID: 29502336.

Delhorme JB, Severac F, Averous G, Glehen O, Passot G, Bakrin N, Marchal F, Pocard M, Lo Dico R, Eveno C, Carrere S, Sgarbura O, Quenet F, Ferron G, Goéré D, Brigand C; French National Network of Peritoneal Surface Malignancies (RENAPE). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg. 2018 May;105(6):668-676. doi: 10.1002/bjs.10716. Epub 2018 Feb 7. PubMed PMID: 29412465.

2017

Guaglio M, Sinukumar S, Kusamura S, Milione M, Pietrantonio F, Battaglia L, Guadagni S, Baratti D, Deraco M. Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. Ann Surg Oncol. 2018 Apr;25 (4):878-884. doi: 10.1245/s10434-017-6305-5. Epub 2017 Dec 21. Erratum in: Ann Surg Oncol. 2018 Jan 19;:. PubMed PMID: 29270877.

Mercier F, Passot G, Villeneuve L, Levine EA, Yonemura Y, Goéré D, Sugarbaker PH, Marolho C, Bartlett DL, Glehen O; BIG-RENAPE Working Group. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Ann Surg Oncol. 2018 Apr;25(4):1094-1100. doi: 10.1245/s10434-017-6299-z. Epub 2017 Dec 13. PubMed PMID: 29238881.

Bouquot M, Dohan A, Gayat E, Barat M, Glehen O, Pocard M, Rousset P, Eveno C. Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score. Ann Surg Oncol. 2018 Mar;25(3):694-701. doi: 10.1245/s10434-017-6275-7. Epub 2017 Nov 30. PubMed PMID: 29192372.

Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M . Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2018 Feb;25(2):404-413. doi: 10.1245/s10434-017-6252-1. Epub 2017 Nov 20. PubMed PMID: 29159742.

Sayyed R, Niazi SK, Siddiqui T. A case for setting-up dedicated peritoneal surface malignancy centers in Pakistan. J Pak Med Assoc. 2017 Nov;67(11):1780-1781. PubMed PMID: 29171584.

Rangarajan K, Chandrakumaran K, Dayal S, Mohamed F, Moran BJ, Cecil TD. The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin. Int J Hyperthermia. 2018 Aug;34(5):559-563. doi: 10.1080/02656736.2017.1384073. Epub 2017 Oct 24. PubMed PMID: 29063804.